Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe disease in humans and other primates caused by viruses in the genus Ebolavirus; the most pathogenic variants of the virus are the members of the species Zaire ebolavirus, with fatality rates as high as 40-90%. The 2014-15 Ebola outbreak is the largest in history, and there is an urgent need to develop effective countermeasures against EVD. Viral proteins such as VP35 block some of the interferon pathways in the host, and these mechanisms contribute to efficient viral replication in dendritic cells, monocytes, and macrophages. EVD is associated with rapid viral dissemination and marked dysregulation of the immune and vascular systems, which leads to hemorrhage and multiple organ failure.
Introduction
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe disease in humans and other primates caused by ebolaviruses. The genus Ebolavirus is one of the three members of the family Filoviridae, together with the genera Marburgvirus and Cuevavirus (Table-1 At present, no proven treatment or preventive vaccine is available for Ebola. However, rapid progress has been achieved in the development of such drugs and vaccines. The aim of this review is to provide an overview of the history, pathogenesis, and treatment of EVD. Current efforts to develop vaccines against EVD are also summarized. (Table-2) . In these outbreaks, 318 cases were identified in DRC with 280 fatalities (88% mortality), and 284 cases were identified in Sudan with 151 fatalities (53% mortality). These epidemics were caused by two distinct species (EBOV and SUDV), but this aspect was not recognized until some years later. The name"Ebola virus"was derived from that of the Ebola river in DRC, because this river was near Yambuku, the focus of the first EBOV outbreak in 1976.
From 1976 to 2013, 1,395 cases of EBOV infection, including 1, 081 fatalities (77% mortality) and 815 cases of SUDV with 425 fatalities (52% mortality) were reported. The fatality rate of EBOV is the highest of the five viruses in the genus Ebolavirus according to the data from 1976 to 2013.
Following the emergence of EBOV and SUDV, TAFV was isolated in 1994 from an ethologist who fell ill after performing a necropsy on a dead chimpanzee in the Taï Forest, Côte dʼIvoire 4) 5) (Table-2 ). The patient was transported to Switzerland for treatment and recovered without sequelae. TAFV infection appears to be symptomatic in humans, but no fatal case has been reported thus far.
BDBV is the fourth species that includes viruses pathogenic to humans (Table-2), and was identified as the causative agent for the outbreak in the Bundibugyo district in western Uganda in 2007 6) , in which there were 149 cases with 37 fatalities (25% mortality). In total, 185 cases of BDBV infection, including 50 fatalities, were reported with a mortality rate of 27%. In 1989, RESTV was identified in a shipment of cynomolgus monkeys housed at quarantine facilities in Reston, Virginia (RESTV is named after Reston) 7) 8) ( . From Guéckédou, EVD was transmitted to Macenta by early February 2014 and subsequently to Kissidougou by late February 2014 10) . EVD further spread into other areas of Guinea, followed by Liberia, Sierra Leone, Nigeria, Senegal, and Mali. Countries outside Africa, the USA, Spain, and the UK were also affected by EVD. There were such 4 cases, including 1 fatality in the USA. The WHO was informed of 1 case in Spain and 1 case in the UK, both of which recovered from EVD.
On August 24, 2014, when the West African EVD outbreak was spreading, the WHO was notified of another unrelated EVD outbreak in the area near Boende town, Équateur province, in western DRC 12) . The index patient was a pregnant woman who butchered a monkey that had been found dead by her husband. She became ill on July 26 and died on August 11. Although the DRC outbreak was also caused by EBOV, the lineage was most closely related to a variant from the 1995 Ebola outbreak in Kikwit in the DRC and not to EBOV variants that are currently circulating in West Africa. This outbreak in DRC was the countryʼs seventh outbreak, and health officials knew the measures to take to contain the outbreak, despite a weak health system and a severe shortage of healthcare staff. The control measures, including case detection, isolation, contact tracing, safe burial, and infection prevention, were applied quickly and worked effectively. On November 21, 2014, the WHO formally declared that the outbreak was over in the DRC.
Virion structure
The virions of ebolaviruses are pleomorphic, appearing as U-shaped, 6-shaped, circular, branched, or filamentous forms with varying lengths (up to 14,000 nm). The Latin word filum means"thread," and the elongated filamentous form characteristic of the viruses in the genera Ebolavirus, Marburgvirus, and Cuevavirus therefore inspired the name filovirus.
The shapes of viral particles are varied, but all forms have a uniform diameter of 80 nm ( Figure-1 ). Virions contain a helical ribonucleoprotein complex or nucleocapsid roughly 50 nm in diameter, which is surrounded by a matrix protein. Virions have a central axial space (-20 nm in diameter) spanning the length of the particle. The viral envelope is derived from the host-cell plasma membrane, which is studded with viral peplomers projecting approximately 10 nm from the surface.
Genome structure
The filovirus virion contains a non-segmented, single-stranded, negative-sense RNA molecule with a length of approximately 19,000 bases. The viral genome encodes seven structural proteins: nucleoprotein (NP), virion protein (VP) 35, VP40, VP30, VP24, glycoprotein (GP), and L (polymerase). The genomic RNA also encodes two nonstructural proteins, namely, soluble GP (sGP) and small soluble GP (ssGP), which are not expressed in marburgviruses 13) 14) . The expression of structural GP and nonstructural ssGP requires transcriptional editing events at the RNA editing site, which has seven uridines on the RNA genomic template. These transcriptional editing events result in the insertion of one or two additional adenosines, leading to the production of GP or ssGP, whereas the unedited transcript produces sGP.
A feature of the filovirus genome is the presence of gene overlaps, as shown in Figure-2 . There are three overlaps (VP35-VP40, GP-VP30, and VP24-L) in the genomes of EBOV, SUDV, BDBV, and TAFV. RESTV has two overlaps in its genome; the GP-VP30 overlap is replaced by an intergenic region. The genomes of marburgviruses contain only a VP30-VP24 overlap, which is not present in ebolaviruses.
Pathogenesis
Three pathogenic ebolaviruses cause the most severe hemorrhagic fever syndromes in humans and non-human primates. EVD is associated with rapid virus replication and a marked dysregulation of the immune and vascular systems. Dendritic cells, monocytes, and macrophages are the primary targets of ebolavirus infection. The viral protein VP35 blocks the production of type I interferons (IFNs) (namely, IFN-α and IFN-β) by preventing the activation of IFN regulatory factor (IRF)-3 and IRF-7 15)-18) . Furthermore, VP35 interferes with the activation of dsRNA-dependent protein kinase PKR 19) and suppresses antiviral RNAi response 20) .
VP24 inhibits the nuclear accumulation of the tyrosine-phosphorylated signal transducer and activator of transcription (STAT) 1 and thereby inhibits the signaling of IFN-α, IFN-β, and IFN-γ ( Figure-3 and Table-3) 21) 22) . These mechanisms contribute to the efficient replication of ebolaviruses in dendritic cells, monocytes, and macrophages. These cells are important in viral dissemination and systemic infection because they are extensively distributed across different tissues and possess migratory capacity through blood and lymphatic systems 23) .
Infected dendritic cells produce only a limited panel of cytokines, without full activation and maturation. It has been shown that active co-stimulatory molecules are silenced and co-inhibitory molecules are expressed in the infected dendritic cells . These factors recruit additional macrophages to the infected areas, which facilitates the expansion of virus infection. This aberrant release of inflammatory substances from monocytes/macrophages may play a role in the induction of T cell apoptosis, together with dendritic cell dysfunction. Immunosuppression resulting from T cell anergy and lymphopenia enables uncontrolled viral replication in the body. The dysregulated production of inflammatory substances causes increased vascular permeability and disseminated intravascular coagulation, which results in hemorrhagic syndromes 27) 28) 32) -38) . Viral replication in hepatocytes inhibits clotting factor synthesis, which also promotes the onset of hemorrhagic diseases. Damage
Figure-3 Pathogenesis model of the Ebola virus diseases
The primary target cells for ebolavirus infection are dendritic cells (DCs) and monocytes/macrophages. In DCs, infection leads to impaired function and dysregulation of lymphocyte co-stimulation. Macrophage infection leads to production of proinflammatory mediators, which may induce bystander apoptosis in lymphocyte populations, thereby contributing to lymphopenia and immunosuppression. Immunosuppression caused by T cell anergy and lymphopenia enables uncontrolled viral replication. Dysregulation of cytokine production causes increased vascular permeability. In addition, the production of tissue factors by infected macrophages leads to the dysregulation of coagulation, which is further reinforced by liver dysfunction that leads to decreased synthesis of liver-derived clotting factors. Infection of adrenal cortical cells results in hypotension and metabolic disorders, which together with coagulopathy contribute to multiple organ failure and shock.
to adrenal cortical cells by viral infection results in hypotension and metabolic disorder. This dysfunction in adrenal glands and the hemorrhagic syndromes caused by increased vascular permeability and liver dysfunction result in hemorrhagic shock and multiple organ failure.
Treatment
To date, no specific therapy has been established for EVD. Supportive care is adopted for EVD patients to maintain blood volume, blood pressure, and electrolyte balance. To save the lives of more EVD patients, it is imperative to develop more effective therapeutics for ebolavirus infection. Based on the understanding of the mechanisms of virus replication and pathogenesis, new targets for therapeutic intervention have been identified, and some drug candidates have shown positive results in animal models (Table-3) .
Favipiravir (Fujifilm Holdings Corporation), also known as T-705 or Avigan, is a broad-spectrum inhibitor of viral RNA polymerase that can inhibit the replication of many RNA viruses, including influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus, and norovirus 39) 40) . Favipiravir was approved in 2014 in Japan for influenza pandemics and has been shown to suppress EBOV replication in cell cultures and to be effective in mice lacking the type I IFN receptor 41) . Initiation of favipiravir administration at day 6 after infection induced prompt viral clearance, reduced biochemical parameters of disease severity, and prevented lethal outcome in 100% of tested animals. Favipiravir also provided 100% protection against aerosol EBOV infection in immune-deficient mice 42) . . ZMapp (Mapp Biopharmaceutical) is a cocktail of three monoclonal antibodies for EBOV, which were selected from six antibodies used in the monoclonal antibody cocktails MB-003 and ZMAb. MB-003 includes three humanized or human-mouse chimeric monoclonal antibodies: c13C6, h13F6, and c6D8 45) . ZMAb is a mixture of three mouse monoclonal antibodies m1H3, m2G4, and m4G7 46) .
To extend the antibody half-life in humans and to facilitate clinical acceptance, the individual murine antibodies in ZMAb were chimerized with human constant regions (c1H3, c2G4, and c4G7). Experiments using guinea pigs and non-human primates were performed to determine the best combination of antibodies. The most effective was the mixture of c13C6 (from MB-003), c2G4, and c4G7 (from cZMAb), which was named ZMapp. ZMapp has been reported to rescue 100% of rhesus macaques when treatment is initiated up to 5 days after EBOV infection 47) . Until the occurrence of the current Ebola outbreak, ZMapp had not been used in humans. However, the FDA allowed ZMapp to be used for EVD patients. In 2014, ZMapp was used to treat seven individuals infected with EBOV. Two of them died and five of them recovered from EVD. The outcome was not considered statistically significant because of the limited number of patients who received ZMapp. The National Institutes of Allergy and Infectious Diseases (NIAID) announced on February 27, 2015 that the Liberian government and NIAID had launched a clinical trial to obtain safety and efficacy data on ZMapp as a treatment for EVD (http: //www. niaid. nih. gov/ news/newsreleases/2015/Pages/ZMapp.aspx).
TKM-Ebola (Tekmira Pharmaceuticals) includes three small interfering RNAs (siRNAs) targeting EBOV L polymerase, membrane-associated protein VP24, and polymerase complex protein VP35. These siRNAs are formulated as stable nucleic acid-lipid particles. A phase 1 clinical trial of TKMEbola was conducted for assessing the safety of TKM-Ebola in healthy people. The FDA placed the trial on clinical hold in July 2014 after some subjects had flu-like responses. In August, the FDA changed the status to"partial hold,"allowing the drug to be used under expanded access for people infected with EBOV. A new phase 2 clinical trial of TKMEbola-Guinea, which is designed specifically to target the strain of EBOV responsible for the present outbreak in Guinea, Liberia, and Sierra Leone, is set to start in Sierra Leone (http: //www. who. int/tdr/news/2015/trial-TKM-ebola-trmnt/en/).
Vaccination
Vaccination is considered one of the most important strategies to control ebolavirus infection. Although no licensed vaccine is available for prevention of EVD to date, significant progress has been made in recent years (Table-4 . Very recently, it was reported that replication-incompetent EBOV lacking VP30 (EBOVΔVP30) protects non-human primates from lethal EBOV infection 50) . To address any potential concerns over recombination events that would restore the replication ability of EBOVΔVP30, virions were additionally treated with hydrogen peroxide (3% final concentration) for inactivation. The vaccines with and without H2O2 were protective in non-human primates, whereas administration of a gamma-irradiated, inactive form of the virus did not protect animals. Currently, at least two vaccine candidates are in advanced stages of development: ChAd3-EBOV from GlaxoSmithKline and the US NIAID, and VSV-EBOV from NewLink Genetics, Merck Vaccines, and the Public Health Agency of Canada (http: //www. who. int/medicines/emp_ebola_q_as /en/).
The ChAd3 vaccine against EBOV infection is a viral-vectored vaccine that expresses the glycoprotein of EBOV. This vaccine is based on a non-replicating adenovirus that primarily infects chimpanzees in the wild. Use of a chimpanzee adenovirus alleviates problems of high levels of pre-existing immunity to human adenoviruses, which may reduce the efficacy of some human adenovirus-based vectors. ChAd3 encoding EBOV glycoprotein was found to protect non-human primates from lethal infection with EBOV. Phase 1 clinical trials to assess the safety and immunogenicity of ChAd3-EBOV vaccine were conducted, and no safety concerns were identified. The vaccine was shown to induce antibody production and cell-mediated immune responses in a dose-dependent manner in healthy adults. A phase 2/3 trial (Partnership for Research on Ebola Vaccines in Liberia; PREVAIL) has been initiated in West Africa for testing the ChAd3-EBOV vaccine (http: //www. niaid. nih. gov/news/QA/Pages/EbolaVaxResultsQ A.aspx).
The VSV-EBOV vaccine consists of a recombinant VSV in which the VSV glycoprotein is deleted and substituted with EBOV glycoprotein. The VSV-based system is advantageous as a vaccine vector because of its replication in mammalian cells, growth to very high titers, and strong induction of innate and adaptive immunity, and because of the very low levels of pre-existing immunity to VSV in the general population. Multiple studies in cynomolgus macaques have shown that a single administration of the vaccine confers a high level of protection against lethal challenge, including that through the aerosol route 51) 52) . In a phase 1 trial, the most common adverse events were pain at the injection-site, myalgia, and fatigue. Because there was a report from another ongoing study of VSV-EBOV regarding arthritis with onset in the second week after injection, participants were specifically queried about the development of new arthralgia, arthritis, or rash during the second week or later after vaccination. One participant reported arthralgia, but this appeared to be unrelated to vaccination with VSV-EBOV. No cases of arthritis were identified. There were no deaths or serious adverse events resulting in withdrawal from the study, and anti-Ebola immune responses were detected in all the volunteers 53) . The VSV-EBOV vaccine has been selected for the phase 2/3 PREVAIL trial, together with ChAd3-EBOV (http: //www. niaid. nih. gov/news/QA/Pages/EbolaVaxResultsQA. aspx). In Guinea, a phase 3 trial was launched on March 7, 2015 to test the VSV-EBOV vaccine for efficacy and effectiveness in preventing EVD (http: //www.who.int/mediacentre/news/releases/2015/ ebola-vaccine-trial/en/). This VSV-based vaccine will also be evaluated in a phase 2/3 trial called the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) (http: //www. cdc. gov/vhf/ebola/ strive/).
Conclusion
EVD is a major threat to humans, and the recent 2014-15 outbreak indicates the need for preparedness against future outbreaks. The development of effective vaccines and therapies is therefore pressingly important. To date, ChAd3-EBOV and VSV-EBOV have shown the most progress as vaccine candidates for EVD. Favipiravir, ZMapp, and TKM-Ebola-Guinea are also moving ahead as promising drug candidates. Compounds that can counteract the antagonistic activity of EBOV proteins against IFN or that can inhibit coagulopathy induced by EBOV infection would be the next drug candidates. The ongoing accumulation of information on the virus and EVD pathogenesis is expected to accelerate the establishment of vaccines, antiviral drugs, and other novel strategies.
